The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25 each and has scaled up its earlier expectations for the proceeds from $125 million.
Prime Medicine is working on a pipeline of 18 programmes aimed at correcting pathogenic mutations and has shown proof of principle for its ‘search-and-replace’ Prime Editing platform in non-human primate studies.
The company was set up by gene-editing pioneers David Liu, who co-founded Editas Medicine and Beam Therapeutics, and Andrew Anzalone of the Broad Institute of MIT and Harvard University.
